RT Journal Article
SR Electronic
T1 Machine learning-optimized Combinatorial MRI scale (COMRISv2) correlates highly with cognitive and physical disability scales in Multiple Sclerosis patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.26.21254405
DO 10.1101/2021.03.26.21254405
A1 Kelly, Erin
A1 Varosanec, Mihael
A1 Kosa, Peter
A1 Sandford, Mary
A1 Prchkovska, Vesna
A1 Moreno-Dominguez, David
A1 Bielekova, Bibiana
YR 2021
UL http://medrxiv.org/content/early/2021/03/28/2021.03.26.21254405.abstract
AB Composite MRI scales of central nervous system tissue destruction correlate stronger with clinical outcomes than their individual components in multiple sclerosis (MS) patients. Using machine learning (ML), we previously developed Combinatorial MRI scale (COMRISv1) solely from semi-quantitative (semi-qMRI) biomarkers. Here, we asked how much better COMRISv2 might become with the inclusion of quantitative (qMRI) volumetric features and employment of more powerful ML algorithm.The prospectively acquired MS patients, divided into training (n=172) and validation (n=83) cohorts underwent brain MRI imaging and clinical evaluation. Neurological examination was transcribed to NeurEx app that automatically computes disability scales. qMRI features were computed by LesionTOADS algorithm. Modified random forest pipeline selected biomarkers for optimal model(s) in the training cohort.COMRISv2 models validated moderate correlation with cognitive disability (Rho = 0.674; Linh’s concordance coefficient [CCC] = 0.458; p<0.001) and strong correlations with physical disability (Spearman Rho = 0.830-0.852; CCC = 0.789-0.823; p<0.001). The NeurEx led to the strongest COMRISv2 model. Addition of qMRI features enhanced performance only of cognitive disability model, likely because semi-qMRI biomarkers measure infratentorial injury with greater accuracy.COMRISv2 models predict most granular clinical scales in MS with remarkable criterion validity, expanding scientific utilization of cohorts with missing clinical data.Competing Interest StatementE.K., M.V., P.K., M.S., and B.B. declare no competing interests. V.P. and D.M-D. were employees of Qmenta at the time of the study.Clinical TrialNCT00794352Funding StatementFunding for this study was provided by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by NIAID scientific review and by the NIH Institutional Review Board. All methods were performed in accordance with the relevant guidelines and regulations. All subjects provided written informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available upon request.